<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article136</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/V-HeFT_II" style="display:block; margin-bottom:10px;">V-HeFT II Original</a></li>
<h2><strong>V-HeFT II</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Enalapril vs. Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure". The New England Journal of Medicine. 1991. 325:303–310.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does enalapril offer a mortality benefit over the combination of hydralazine and isosorbide dinitrate in men with chronic congestive heart failure receiving digoxin and diuretic therapy?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In men with chronic congestive heart failure on standard therapy with digoxin and diuretics, treatment with enalapril resulted in a significant reduction in 2-year mortality compared with hydralazine and isosorbide dinitrate, mainly due to a reduction in sudden deaths.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel-group, randomized, active-control trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Men aged 18-75 with chronic heart failure<br/>
- Cardiac dysfunction with reduced exercise tolerance (cardiothoracic ratio ≥0.55, left ventricular internal diameter &gt;2.7 cm/m^2 at diastole, or ejection fraction &lt;0.45)<br/>
<br/>
Exclusion Criteria<br/>
- Myocardial infarction or cardiac surgery within the last 3 months, limiting angina, significant obstructive valvular or lung disease, other life-limiting comorbidities<br/>
<br/>
Baseline Characteristics<br/>
- Average age 61 years, majority with ejection fraction &lt;0.45, 53% had coronary artery disease as primary cause of heart failure<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Enalapril 20 mg daily (n=403) or<br/>
- Hydralazine 300 mg plus Isosorbide dinitrate 160 mg daily (n=401)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Mortality after two years: significantly lower in the enalapril group (18% vs. 25%; P=0.016)<br/>
<br/>
Secondary Outcomes<br/>
- Overall mortality: tended to be lower in the enalapril group (P=0.08)<br/>
- Cause of death: Reduction in sudden deaths, without or with premonitory worsening of cardiac status in the enalapril group<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Lack of a placebo group due to ethical concerns following the results of V-HeFT I<br/>
- Results may not be generalizable to women or those with severe heart failure<br/>
- The parallel design did not allow for direct testing of any additive effects of combination therapy<br/>
- Limited information on quality of life and functional status improvements <br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by the Cooperative Studies Program of the Medical Research Service, Department of Veterans Affairs Central Office, Washington, D.C.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
N/A
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
